Critical Outcome Technologies’ proprietary CHEMSAS® technology would appear to be both topical and relevant in light of the recent new drug approvals by the FDA. If medical science is to increase the impact on disease, the goal must be to increase the number of compounds being submitted for approval. This is the fundamental premise of using CHEMSAS® at the discovery stage; to identify novel compounds (or repurpose / modify existing compounds) with a high probability of being successfully developed for the specific targets chosen.
With CHEMSAS®, failures occur quickly and cheaply in computer simulations, with only computationally successful drugs moving forward for development. The speed of identification and probability of success for such drug candidates can increase the number being developed and hence submitted for approval after the requisite clinical trials. If we think of this as portfolio theory for example, we could have ten compounds being developed from CHEMSAS®, rather than say 100 in the traditional process, but the success rate would be much higher (i.e. 9 out of 10 vs. 1 in 100).